+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Macular Edema Treatment Market by Treatment Type, Product Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Diabetic Macular Edema Treatment Market by Treatment Type, Product Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Diabetic Macular Edema Treatment Market by Treatment Type, Product Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888142
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetic Macular Edema Treatment Market grew from USD 3.12 billion in 2024 to USD 3.28 billion in 2025. It is expected to continue growing at a CAGR of 5.15%, reaching USD 4.22 billion by 2030.

Navigating the Complex Landscape of Diabetic Macular Edema

Diabetic macular edema presents a formidable challenge, placing millions at risk of irreversible vision loss and substantially escalating healthcare burdens. As the global prevalence of diabetic retinopathy accelerates in tandem with rising diabetes rates, stakeholders across the value chain must navigate a complex therapeutic environment shaped by evolving clinical protocols, reimbursement dynamics, and patient expectations.

Against this backdrop, innovation has surged across pharmacological and procedural interventions, propelled by advances in molecular science, drug delivery platforms, and real‐world evidence generation. Anti‐VEGF agents, sustained‐release corticosteroid implants, and refined laser photocoagulation techniques each offer distinct efficacy and safety profiles. Concurrently, healthcare systems grapple with optimizing care pathways that balance clinical outcomes, treatment adherence, and cost containment.

This report delivers a comprehensive executive summary that elucidates the transformative shifts reshaping the diabetic macular edema landscape. By unpacking progressive therapeutic trends, examining the ramifications of evolving US tariff structures, and distilling deep segmentation and regional insights, we equip decision‐makers with the strategic clarity needed to navigate market uncertainties and seize growth opportunities.

Transformative Innovations Redefining Treatment Pathways

Recent years have witnessed groundbreaking shifts that are redefining diabetic macular edema management. The maturation of anti‐VEGF biologics has established these agents as the cornerstone of therapy, yet the emergence of biosimilars promises to democratize access and exert downward pricing pressure. At the same time, innovations in sustained‐release drug‐delivery implants are reducing injection frequency, thereby alleviating patient burden and improving adherence.

Parallel advances in digital retina imaging, powered by artificial intelligence and telemedicine platforms, are catalyzing earlier detection, personalized treatment planning, and remote patient monitoring. This convergence of diagnostic precision and therapeutic innovation is fostering more proactive intervention strategies and enabling care models that extend beyond traditional clinic visits.

Moreover, the integration of real‐world data into regulatory submissions and reimbursement dossiers is accelerating market entry and reimbursement acceptance, reshaping the competitive dynamics between established industry incumbents and agile biotech challengers. Taken together, these transformative trends are forging a more patient‐centric, data‐driven, and economically sustainable trajectory for diabetic macular edema care.

Assessing the 2025 US Tariff Recalibration on Supply and Costs

The implementation of revised United States tariff measures in 2025 is poised to exert significant influence across the diabetic macular edema supply chain. As pharmaceutical ingredients, specialty polymers for sustained‐release implants, and precision laser equipment components face recalibrated import duties, manufacturers and providers will confront upward pressure on production and operational costs.

In response, global suppliers are recalibrating sourcing strategies, diversifying manufacturing footprints, and accelerating vertical integration to mitigate tariff‐induced margin erosion. Simultaneously, payers and integrated delivery networks are intensifying their focus on value‐based contracting, demanding demonstrable outcomes linked to total cost of care reductions.

Supply‐chain optimization initiatives, including nearshoring raw material production and consolidating distribution agreements, are emerging as critical levers to preserve price competitiveness. At the same time, cross‐border partnerships and co‐development alliances are gaining traction, enabling technology transfer and shared risk models that align stakeholder incentives amidst evolving trade policies.

Unearthing Critical Insights Across Treatment, Product, and Channel Segments

An in‐depth segmentation by treatment type reveals that anti‐VEGF therapy comprises four primary molecules-aflibercept, bevacizumab, brolucizumab, and ranibizumab-each differentiated by dosing frequency, receptor affinity, and safety profile. Corticosteroid therapy is represented by dexamethasone and fluocinolone acetonide implants, offering sustained drug release for patients with suboptimal anti‐VEGF response or contraindications. Laser photocoagulation subdivides into focal and grid techniques, reflecting advances in precision and energy delivery that minimize collateral retinal damage.

When products are classified by type, a clear dichotomy emerges between branded innovations that command premium pricing and generic equivalents that facilitate broader market penetration among cost‐sensitive segments. Further scrutiny of administration routes underscores the predominance of intravitreal injections as the standard of care, while sustained‐release implants gain momentum for reducing treatment labor and improving patient adherence through extended therapeutic windows.

Distribution channel analysis highlights hospital pharmacies as vital hubs for acute care delivery, retail pharmacies for outpatient continuity, and specialty pharmacies as expert facilitators for high‐cost biologics requiring cold‐chain logistics and patient education. Finally, end‐user insights identify hospitals as primary treatment locales for complex cases, with specialty clinics increasingly catering to routine management and follow‐up care, thereby shaping referral patterns and resource allocation.

Divergent Regional Dynamics Shaping Market Growth Trajectories

Regional dynamics in diabetic macular edema underscore pronounced variability in disease burden, access to care, and reimbursement frameworks. In the Americas, robust clinical trial ecosystems and established reimbursement pathways support rapid uptake of novel biologics and drug‐delivery innovations. Meanwhile, downward pricing pressure from biosimilar entrants is intensifying competition and catalyzing broader population access.

Within Europe, the Middle East, and Africa, heterogeneity in healthcare infrastructure and reimbursement fragmentation presents both challenges and growth vectors. Select markets in Western Europe exhibit high per‐capita adoption of advanced therapies, whereas emerging economies across the region rely heavily on cost‐effective corticosteroid implants and generic anti‐VEGF equivalents to manage healthcare expenditures.

In the Asia‐Pacific landscape, rapidly expanding diabetic populations are driving significant demand growth, with governments investing in screening programs and tele‐ophthalmology networks to bridge geographic gaps. Local manufacturing initiatives and public-private partnerships are fostering domestic production of generics and biosimilars, positioning the region as a pivotal growth engine for the global diabetic macular edema market.

Competitive Dynamics and Strategic Positioning of Market Leaders

Leading industry players continue to vie for dominance in the diabetic macular edema domain by leveraging differentiated pipelines, strategic alliances, and value‐based care models. One company has fortified its position through the global rollout of its flagship anti‐VEGF agent, backed by extensive real‐world evidence highlighting superior visual acuity gains and an established safety profile.

A second major innovator has pivoted toward sustained‐release corticosteroid implants, securing premium reimbursement and forging co‐development collaborations to extend franchise applications into adjacent ophthalmic indications. A third competitor, initially renowned for its retinal imaging solutions, has diversified into injectable biologics via targeted acquisitions and in‐licensing agreements, accelerating its entry into this high‐value market.

Additionally, agile biotech firms and emerging biosimilar manufacturers are challenging established players by offering cost‐competitive alternatives that emphasize interchangeable status and streamlined regulatory pathways. Strategic partnerships between device manufacturers and pharmaceutical sponsors are also gaining momentum, enabling integrated therapeutic and diagnostic solutions that promise enhanced patient outcomes and optimized care pathways.

Strategic Imperatives for Sustained Market Leadership

Industry leaders must embrace a multifaceted strategy that aligns innovation with affordability to capture the next wave of diabetic macular edema growth. First, prioritizing investment in sustained‐release drug‐delivery platforms will address patient adherence challenges and differentiate product portfolios in a crowded anti‐VEGF landscape.

Concurrently, pursuing strategic alliances with biosimilar developers can facilitate access to emerging low‐cost alternatives, enabling a dual‐pronged approach that balances premium branded offerings with economically accessible solutions. Expanding diagnostic capabilities through AI‐enabled imaging and telemedicine partnerships will further strengthen market positioning by enabling proactive disease management and supporting outcome‐based reimbursement discussions.

Supply‐chain resilience should be reinforced through diversified manufacturing footprints and nearshoring initiatives to mitigate the financial impact of trade policy shifts. Lastly, cultivating robust payer engagement strategies that highlight total cost of care benefits can unlock formulary placement and secure value‐based contracting arrangements, ensuring sustained market access.

Robust Multi‐Source Methodology Underpinning Market Insights

This research integrates a rigorous methodology combining primary and secondary data sources to ensure comprehensive insights. Primary research involved in‐depth interviews with ophthalmologists, payers, supply‐chain executives, and industry experts, generating qualitative perspectives on clinical adoption, reimbursement trends, and procurement strategies. Complementary quantitative analysis drew from proprietary databases, peer‐reviewed literature, regulatory filings, and real‐world evidence repositories to validate market dynamics and segmentation frameworks.

Data triangulation techniques were applied to reconcile disparate data points, enhance reliability, and identify emerging patterns. Statistical models assessed the relative impact of macroeconomic variables, policy shifts, and competitive activity on market share evolution. The research team also conducted cross‐regional comparisons to account for geographic heterogeneity in healthcare infrastructure, regulatory environments, and patient demographics.

Peer review protocols and external advisory panels further bolstered methodological rigor, ensuring that findings reflect the latest industry developments while adhering to stringent quality standards.

Synthesizing Key Insights to Drive Strategic Clarity

In summary, diabetic macular edema is undergoing a period of accelerated transformation driven by therapeutic innovation, evolving policy landscapes, and shifting competitive dynamics. Stakeholders must adapt to the growing prominence of biosimilars, leverage sustained‐release technologies to improve patient adherence, and navigate tariff‐induced cost pressures with agile supply‐chain strategies.

Regional nuances offer distinct growth opportunities, from the Americas’ established reimbursement structures to the Asia‐Pacific’s burgeoning diabetic populations. Market leaders can secure competitive advantage by aligning high‐value clinical outcomes with cost‐effectiveness and forging collaborative partnerships across the ecosystem.

This comprehensive executive overview lays the foundation for informed decision‐making, equipping industry participants with the strategic clarity needed to capitalize on emerging trends and mitigate risks in the diabetic macular edema landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Anti-Vegf Therapy
      • Aflibercept
      • Bevacizumab
      • Brolucizumab
      • Ranibizumab
    • Corticosteroid Therapy
      • Dexamethasone Implant
      • Fluocinolone Acetonide Implant
    • Laser Photocoagulation
      • Focal Laser
      • Grid Laser
  • Product Type
    • Branded Products
    • Generic Products
  • Route Of Administration
    • Intravitreal Injection
    • Sustained Release Implant
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • End User
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Alimera Sciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetic Macular Edema Treatment Market, by Treatment Type
8.1. Introduction
8.2. Anti-Vegf Therapy
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Brolucizumab
8.2.4. Ranibizumab
8.3. Corticosteroid Therapy
8.3.1. Dexamethasone Implant
8.3.2. Fluocinolone Acetonide Implant
8.4. Laser Photocoagulation
8.4.1. Focal Laser
8.4.2. Grid Laser
9. Diabetic Macular Edema Treatment Market, by Product Type
9.1. Introduction
9.2. Branded Products
9.3. Generic Products
10. Diabetic Macular Edema Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intravitreal Injection
10.3. Sustained Release Implant
11. Diabetic Macular Edema Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
11.4. Specialty Pharmacies
12. Diabetic Macular Edema Treatment Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
13. Americas Diabetic Macular Edema Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Diabetic Macular Edema Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Regeneron Pharmaceuticals, Inc.
16.3.2. Novartis AG
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.4. AbbVie Inc.
16.3.5. Bayer AG
16.3.6. Alimera Sciences, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY FLUOCINOLONE ACETONIDE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY FOCAL LASER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY GRID LASER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY BRANDED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY GENERIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SUSTAINED RELEASE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 54. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 55. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 113. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 127. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 128. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 129. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 135. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 136. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 137. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 167. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 169. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 183. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 184. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 185. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 247. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 248. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 249. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 272. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 273. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 274. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 280. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 281. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 282. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 288. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID THERAPY, 2018-2030 (USD MILLION)
TABLE 289. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 290. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET S

Companies Mentioned

The companies profiled in this Diabetic Macular Edema Treatment market report include:
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Alimera Sciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.22 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Diabetic Macular Edema (DME) Global Market Report 2025 - Product Image

Diabetic Macular Edema (DME) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Diabetic Macular Edema Treatment - Global Strategic Business Report - Product Image

Diabetic Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Non-Infectious Macular Edema Treatment - Global Strategic Business Report - Product Image

Non-Infectious Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Macular Edema and Macular Degeneration Market Report 2025 - Product Image

Macular Edema and Macular Degeneration Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 253 Pages
  • Global
From

About the Market

Diabetic Macular Edema (DME) is a common complication of diabetes that affects the macula, the central part of the retina responsible for sharp, central vision. DME is caused by the accumulation of fluid in the macula, leading to swelling and blurred vision. Treatment for DME typically involves the use of Optical Disorders Drugs, such as anti-VEGF agents, corticosteroids, and other drugs. Anti-VEGF agents are the most commonly used drugs for DME, as they can reduce the amount of fluid in the macula and improve vision. Corticosteroids are also used to reduce inflammation and swelling in the macula. Other drugs, such as carbonic anhydrase inhibitors, can also be used to reduce fluid accumulation in the macula. The DME Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Regeneron Pharmaceuticals, Novartis, Allergan, Roche, and Bayer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.